- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 213/40 - Acylated substituent nitrogen atom
Patent holdings for IPC class C07D 213/40
Total number of patents in this class: 548
10-year publication summary
|
58
|
51
|
41
|
36
|
34
|
35
|
34
|
25
|
15
|
12
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| H. Lundbeck A/S | 1232 |
10 |
| The Regents of the University of California | 20778 |
9 |
| Givaudan SA | 1974 |
9 |
| AstraZeneca AB | 2819 |
8 |
| The General Hospital Corporation | 4871 |
8 |
| The Scripps Research Institute | 1340 |
8 |
| Corteva Agriscience LLC | 2640 |
8 |
| Amgen Inc. | 4429 |
7 |
| The Broad Institute, Inc. | 1979 |
7 |
| Ono Pharmaceutical Co., Ltd. | 421 |
7 |
| Bristol-myers Squibb Company | 4751 |
6 |
| Massachusetts Institute of Technology | 10254 |
6 |
| Gilead Sciences, Inc. | 2226 |
6 |
| Nihon Nohyaku Co., Ltd. | 325 |
6 |
| Nippon Soda Co., Ltd. | 882 |
6 |
| PTC Therapeutics, Inc. | 475 |
6 |
| Taisho Pharmaceutical Co., Ltd. | 850 |
6 |
| Calico Life Sciences LLC | 111 |
6 |
| Bayer Pharma AG | 1009 |
5 |
| Abbvie Inc. | 1824 |
5 |
| Other owners | 409 |